Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis

  • Ferreiro-Iglesias, Aida
  • Montes, Ariana
  • Pérez-Pampin, Eva
  • Cañete, Juan D.
  • Raya-Álvarez, Enrique
  • Magro-Checa, César
  • Vasilopoulos, Yiannis
  • Sarafidou, Theologia
  • Cáliz, Rafael
  • Ferrer, Miguel Ángel
  • Joven, Beatriz
  • Carreira, Patricia
  • Balsa, Alejandro
  • Pascual-Salcedo, Dora
  • Blanco García, Francisco J
  • Moreno-Ramos, Manuel J.
  • Fernández-Nebro, Antonio
  • Ordóñez, María del Carmen
  • Alegre-Sancho, JJ
  • Narváez, Javier
  • Navarro-Sarabia, Federico
  • Moreira, Virginia
  • Valor, Lara
  • García-Portales, Rosa
  • Márquez, Ana
  • Martín, Javier
  • Gómez-Reino, Juan J.
  • González, Antonio
[Abstract] Genetic biomarkers could be useful for orienting treatment of patients with rheumatoid arthritis (RA), but none has been convincingly validated yet. Putative biomarkers include 14 single nucleotide polymorphisms that have shown association with response to TNF inhibitors (TNFi) in candidate gene studies and that we assayed here in 755 RA patients. Three of them, in the PTPRC, IL10 and CHUK genes, were significantly associated with response to TNFi. The most significant result was obtained with rs10919563 in PTPRC, which is a confirmed RA susceptibility locus. Its RA risk allele was associated with improved response (B=0.33, P=0.006). This is the second independent replication of this biomarker (P=9.08 × 10(-8) in the combined 3003 RA patients). In this way, PTPRC has become the most replicated genetic biomarker of response to TNFi. In addition, the positive but weaker replication of IL10 and CHUK should stimulate further validation studies., Funding was provided by grants PI11/01048, PI12/01909 and by RETICS Program, RD12/0009/0008 and RD12/0009/0004 (RIER) of the Instituto de Salud Carlos III (Spain) that are partially financed by the European Regional Development Fund of the European Union.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility, A case-only study

  • Montes, Ariana
  • Perez-Pampin, Eva
  • Navarro-Sarabia, Federica
  • Moreira, Virginia
  • Rodríguez de la Serna, Arturo
  • Magallares López, Berta|||0000-0002-4691-2342
  • Vasilopoulos, Yiannis
  • Sarafidou, Theologia
  • Fernández-Nebro, Antonio|||0000-0002-2962-9844
  • Ordóñez, María del Carmen
  • Narváez, Javier|||0000-0002-1614-8064
  • Cañete, Juan D.|||0000-0003-2606-0573
  • Márquez, Ana|||0000-0001-9913-7688
  • Pascual-Salcedo, Dora
  • Joven, Beatriz
  • Carreira, Patrícia
  • Moreno Ramos, Manuel José|||0000-0003-3800-7382
  • Caliz, Rafael
  • Ferrer, Miguel Ángel
  • Garcia-Portales, Rosa
  • Blanco-García, F.J.|||0000-0001-9821-7635
  • Magro, César
  • Raya, Enrique
  • Valor, Lara
  • Alegre-Sancho, Juan José|||0000-0003-1641-0875
  • Balsa, Alejandro|||0000-0001-8070-7062
  • Martín, Javier|||0000-0002-2202-0622
  • Plant, Darren
  • Isaacs, John
  • Morgan, Ann W.
  • Barton, Anne|||0000-0003-3316-2527
  • Wilson, Anthony G.
  • Gómez-Reino, Juan J.
  • Gonzalez, Antonio
Introduction: We have hypothesized that incompatibility between the G1m genotype of the patient and the G1m1 and G1m17 allotypes carried by infliximab (INX) and adalimumab (ADM) could decrease the efficacy of these anti-tumor necrosis factor (anti-TNF) antibodies in the treatment of rheumatoid arthritis (RA). Methods: The G1m genotypes were analyzed in three collections of patients with RA totaling 1037 subjects. The first, used for discovery, comprised 215 Spanish patients. The second and third were successively used for replication. They included 429 British and Greek patients and 393 Spanish and British patients, respectively. Two outcomes were considered: change in the Disease Activity Score in 28 joint (DAS28) and the European League Against Rheumatism (EULAR) response criteria. Results: An association between less response to INX and incompatibility of the G1m1,17 allotype was found in the discovery collection at 6 months of treatment (P = 0.03). This association was confirmed in the replications (P = 0.02 and 0.08, respectively) leading to a global association (P = 0.001) that involved a mean difference in DAS28 of 0.4 units between compatible and incompatible patients (2.3 ± 1.5 in compatible patients vs. 1.9 ± 1.5 in incompatible patients) and an increase in responders and decrease in non-responders according to the EULAR criteria (P = 0.03). A similar association was suggested for patients treated with ADM in the discovery collection, but it was not supported by replication. Conclusions: Our results suggest that G1m1,17 allotypes are associated with response to INX and could aid improved therapeutic targeting in RA.